A selected list of publications:

1. Biology and Therapy of Castration Resistant Prostate Cancer

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazil L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg, ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine 2010 Dec;16(12):1414-20.

Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. PMID: 27694579 Free PMC Article.

Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferriere JM. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancer. Urol Oncol. 2010 Sept-Oct;28(5):473-9.

Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RE  Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 2010 Mar-Apr;28(2):180-8.

Hara T, Miyazaki H, Tran C, Reiter RE. Androgen receptor mediates invasiveness of prostate cancer cells. Cancer Res. 2008 Feb 15; 68(4):1128-35.

Lam JS, Reiter RE Stem cells in prostate and prostate cancer development. Urol Oncol. 2006 Mar-Apr; 24(2):131-40.

Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Nati Acad Sci U S A. 2001 Feb 27;98(5):2658-63.

Craft N, Chhor C, Tran C, Belldegrun A, deKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999 Oct 1;59(19):5030-6.

Bui M, Reiter RE. Stem cell genes in androgen independent prostate cancer. Cancer Metastasis Rev. 1998-1999;17(4):391-9.

Klein KA*, Reiter RE*, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 1997 Apr;3(4):402-8. (* indicates co-first authorship).

2. PET and Optical Imaging

Zhang M, Zetlitz KA, Kobayashi N, Wu AM, Reiter RE. Near-infrared-dye labeled anti-Prostate Stem Cell Antigen (PSCA) A11 minibody enables intraoperative fluorescence imaging and targeted surgery in translational mouse models of prostate cancer. Clinical Cancer Research, 2019.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Fluciclovine PET-CT and Ga-PSMA-11 PET CT in patients with early biochemical recurrence after prostatectomy: a prospective single centre single arm comparative imaging trials. Lancet Oncol. 2019 Jul 30.

Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.  J Nucl Med. 2016 Dec;57(12):1858-1864. PMID: 27516450.

Sonn GA, Behesnelian A, Zhang Z, Lepin EJ, Bentolila LA, Lawrence DJP, Zettlitz KA, Wu AM, Reiter RE; Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Prostate Cancer Xenografts in Real-Time. Clinical Cancer Res., October, 2015.

3. MRI Imaging

Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter REDo contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.  Cancer. 2019 Sep 1;125(17):2955-2964.

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter REMolecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. Eur Urol. 2019 Jul;76(1):18-23.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE. PI-RADSv2 category on 3 tesla multiparametric prostate MRI predicts oncologic outcomes in Gleason 3+4 prostate cancer on biopsy. (COVER ARTICLE)  J Urol. 2018 Aug 21.

Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol. 2018 Mar 7. (COVER ARTICLE in this issue).

Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker ER, Lu DSK, Reiter RE. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging (COVER ARTICLE in May 2019 print edition). Eur Urol. 2018 Nov 30.

To see more publications, go to: https://pubmed.ncbi.nlm.nih.gov/?term=robert+e.+reiter